{"DataElement":{"publicId":"2518935","version":"1","preferredName":"Agent Protocol Name","preferredDefinition":"The name of the pertaining agent as specified in a protocol.","longName":"AGT_PROT_NM","context":"DCP","contextVersion":"1","DataElementConcept":{"publicId":"2182015","version":"1","preferredName":"Agent Protocol","preferredDefinition":"the drug agent used for the protocol.","longName":"AGT_PROT","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2223333","version":"1","preferredName":"Agent","preferredDefinition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","longName":"C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F62B10F2-76A7-2830-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-02","endDate":null,"createdBy":"UMLLOADER","dateCreated":"2005-05-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177383","version":"1","preferredName":"Protocol","preferredDefinition":"An action plan for a clinical trial.  The plan states what the study will do, how, and why.  It explains how many people will be in it, who is eligible to participate, what study agents or other interventions they will be given, what tests they will receive and how often, and what information will be gathered.","longName":"Protocol","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Clinical Study Protocol","conceptCode":"C25320","definition":"A formal document that describes a complete plan of research activity in the framework of a clinical study; specifically, the study objective(s), design, methodology, eligibility requests for prospective subjects and controls; intervention regimen(s), proposed methods of analysis of data; statistical considerations, and organization of the study. The protocol usually also provides the background and rationale for the study, but these could be represented in other protocol referenced documents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-526A-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D5FE454A-7465-5F54-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-03-19","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-03-19","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Use caBIG NCIt based OC instead. - dw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2518933","version":"1","preferredName":"Agent Protocol Name","preferredDefinition":"The name of the pertaining agent as specified in a protocol.","longName":"AGT_PROT_NM","context":"DCP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"aspirin 81 mg/placebo","valueDescription":"aspirin 81mg/placebo","ValueMeaning":{"publicId":"2580796","version":"1","preferredName":"aspirin 81mg/placebo","longName":"2580796","preferredDefinition":"aspirin 81mg/placebo","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-08A9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-08","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-09-08","modifiedBy":"MAESKEB","dateModified":"2006-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1CF65EF4-5446-3B6C-E044-0003BA3F9857","beginDate":"2006-09-08","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-09-08","modifiedBy":"MAESKEB","dateModified":"2006-09-08","deletedIndicator":"No"},{"value":"aspirin 325 mg/placebo","valueDescription":"aspirin 325 mg/placebo","ValueMeaning":{"publicId":"2580797","version":"1","preferredName":"aspirin 325 mg/placebo","longName":"2580797","preferredDefinition":"aspirin 325 mg/placebo","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-08AA-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-08","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-09-08","modifiedBy":"MAESKEB","dateModified":"2006-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1CF65EF4-5452-3B6C-E044-0003BA3F9857","beginDate":"2006-09-08","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-09-08","modifiedBy":"MAESKEB","dateModified":"2006-09-08","deletedIndicator":"No"},{"value":"Esomeprazole","valueDescription":"Esomeprazole","ValueMeaning":{"publicId":"4926632","version":"1","preferredName":"Esomeprazole","longName":"4926632","preferredDefinition":"The S-isomer of omeprazole, with gastric proton pump inhibitor activity. In the acidic compartment of parietal cells, esomeprazole is protonated and converted into the active achiral sulfenamide; the active sulfenamide forms one or more covalent disulfide bonds with the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase), thereby inhibiting its activity and the parietal cell secretion of H+ ions into the gastric lumen, the final step in gastric acid production. H+/K+ ATPase is an integral membrane protein of the gastric parietal cell.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Esomeprazole","conceptCode":"C65538","definition":"The S-isomer of omeprazole, with gastric proton pump inhibitor activity. In the acidic compartment of parietal cells, esomeprazole is protonated and converted into the active achiral sulfenamide; the active sulfenamide forms one or more covalent disulfide bonds with the proton pump hydrogen-potassium adenosine triphosphatase (H+/K+ ATPase), thereby inhibiting its activity and the parietal cell secretion of H+ ions into the gastric lumen, the final step in gastric acid production. H+/K+ ATPase is an integral membrane protein of the gastric parietal cell.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1C6A52B5-06A7-EAD6-E050-BB89AD435EF7","latestVersionIndicator":"Yes","beginDate":"2015-08-03","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-08-03","modifiedBy":"ONEDATA","dateModified":"2015-08-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1C6A52B5-06BF-EAD6-E050-BB89AD435EF7","beginDate":"2006-09-08","endDate":null,"createdBy":"MAESKEB","dateCreated":"2015-08-03","modifiedBy":"ONEDATA","dateModified":"2015-08-03","deletedIndicator":"No"},{"value":"Megestrol Acetate and Metformin","valueDescription":"Megestrol Acetate And Metformin","ValueMeaning":{"publicId":"7373697","version":"1","preferredName":"Megestrol Acetate And Metformin","longName":"7373697","preferredDefinition":"The acetate salt form of megestrol, a synthetic derivative of the naturally occurring female sex hormone progesterone with potential anti-estrogenic and antineoplastic activity. Mimicking the action of progesterone, megestrol acetate binds to and activates nuclear progesterone receptors in the reproductive system, and causes the ligand-receptor complex to be translocated to the nucleus where it binds to and promotes expression of target genes. This leads to an alteration in protein synthesis, which modulates cell growth of reproductive tissues. Due to the negative feedback mechanism seen with progesterone, megestrol also blocks luteinizing hormone (LH) release from the pituitary gland, thereby leading to an inhibition of ovulation and an alteration in the cervical mucus and endometrium. Furthermore, without stimulation of LH, estrogen release from the ovaries is stopped, hence impedes the growth of estrogen-sensitive tumor cells.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: An agent belonging to the biguanide class of antidiabetics with antihyperglycemic activity. Metformin is associated with a very low incidence of lactic acidosis. This agent helps reduce LDL cholesterol and triglyceride levels, and is not associated with weight gain, and prevents the cardiovascular complications of diabetes. Metformin is not metabolized and is excreted unchanged by the kidneys.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Megestrol Acetate","conceptCode":"C1156","definition":"The acetate salt form of megestrol, a synthetic derivative of the naturally occurring female sex hormone progesterone with potential anti-estrogenic and antineoplastic activity. Mimicking the action of progesterone, megestrol acetate binds to and activates nuclear progesterone receptors in the reproductive system, and causes the ligand-receptor complex to be translocated to the nucleus where it binds to and promotes expression of target genes. This leads to an alteration in protein synthesis, which modulates cell growth of reproductive tissues. Due to the negative feedback mechanism seen with progesterone, megestrol also blocks luteinizing hormone (LH) release from the pituitary gland, thereby leading to an inhibition of ovulation and an alteration in the cervical mucus and endometrium. Furthermore, without stimulation of LH, estrogen release from the ovaries is stopped, hence impedes the growth of estrogen-sensitive tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Metformin","conceptCode":"C61612","definition":"An agent belonging to the biguanide class of antidiabetics with antihyperglycemic activity. Metformin is associated with a very low incidence of lactic acidosis. This agent helps reduce LDL cholesterol and triglyceride levels, and is not associated with weight gain, and prevents the cardiovascular complications of diabetes. Metformin is not metabolized and is excreted unchanged by the kidneys.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AB94FCB6-06E7-5985-E053-4EBD850A2D7A","latestVersionIndicator":"Yes","beginDate":"2020-07-29","endDate":null,"createdBy":"LISU","dateCreated":"2020-07-29","modifiedBy":"ONEDATA","dateModified":"2020-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB94FCB6-0700-5985-E053-4EBD850A2D7A","beginDate":"2020-07-29","endDate":null,"createdBy":"LISU","dateCreated":"2020-07-29","modifiedBy":"ONEDATA","dateModified":"2020-07-29","deletedIndicator":"No"},{"value":"Megestrol Acetate","valueDescription":"Megestrol Acetate","ValueMeaning":{"publicId":"3379278","version":"1","preferredName":"Megestrol Acetate","longName":"3379278","preferredDefinition":"The acetate salt form of megestrol, a synthetic derivative of the naturally occurring female sex hormone progesterone with anti-estrogenic activity and used in breast cancer treatment. Mimicking the action of progesterone, megestrol acetate binds to and activates nuclear progesterone receptors in the reproductive system, and causes the ligand-receptor complex to be translocated to the nucleus where it binds to and promotes expression of target genes. This leads to an alteration in protein synthesis, which modulates cell growth of reproductive tissues. Due to the negative feedback mechanism seen with progesterone, megestrol also blocks luteinizing hormone (LH) release from the pituitary gland, thereby leading to an inhibition of ovulation and an alteration in the cervical mucus and endometrium. Furthermore, without stimulation of LH, estrogen release from the ovaries is stopped, hence impedes the growth of estrogen-sensitive tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Megestrol Acetate","conceptCode":"C1156","definition":"The acetate salt form of megestrol, a synthetic derivative of the naturally occurring female sex hormone progesterone with potential anti-estrogenic and antineoplastic activity. Mimicking the action of progesterone, megestrol acetate binds to and activates nuclear progesterone receptors in the reproductive system, and causes the ligand-receptor complex to be translocated to the nucleus where it binds to and promotes expression of target genes. This leads to an alteration in protein synthesis, which modulates cell growth of reproductive tissues. Due to the negative feedback mechanism seen with progesterone, megestrol also blocks luteinizing hormone (LH) release from the pituitary gland, thereby leading to an inhibition of ovulation and an alteration in the cervical mucus and endometrium. Furthermore, without stimulation of LH, estrogen release from the ovaries is stopped, hence impedes the growth of estrogen-sensitive tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91A08CE-C5F5-784E-E040-BB89AD435DD1","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB94FCB6-0714-5985-E053-4EBD850A2D7A","beginDate":"2020-07-29","endDate":null,"createdBy":"LISU","dateCreated":"2020-07-29","modifiedBy":"ONEDATA","dateModified":"2020-07-29","deletedIndicator":"No"},{"value":"Metformin","valueDescription":"Metformin","ValueMeaning":{"publicId":"3189685","version":"1","preferredName":"Metformin","longName":"3189685v1.00","preferredDefinition":"An agent belonging to the biguanide class of antidiabetics with antihyperglycemic activity. Metformin is associated with a very low incidence of lactic acidosis. This agent helps reduce LDL cholesterol and triglyceride levels, and is not associated with weight gain, and prevents the cardiovascular complications of diabetes. Metformin is not metabolized and is excreted unchanged by the kidneys.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metformin","conceptCode":"C61612","definition":"An agent belonging to the biguanide class of antidiabetics with antihyperglycemic activity. Metformin is associated with a very low incidence of lactic acidosis. This agent helps reduce LDL cholesterol and triglyceride levels, and is not associated with weight gain, and prevents the cardiovascular complications of diabetes. Metformin is not metabolized and is excreted unchanged by the kidneys.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BB1D0F5-1252-2360-E040-BB89AD4328D8","latestVersionIndicator":"Yes","beginDate":"2011-02-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-02-07","modifiedBy":"MMADDINENI","dateModified":"2022-10-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"AB94FCB6-071F-5985-E053-4EBD850A2D7A","beginDate":"2020-07-29","endDate":null,"createdBy":"LISU","dateCreated":"2020-07-29","modifiedBy":"ONEDATA","dateModified":"2020-07-29","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435024","version":"1","preferredName":"Drug or Chemical","preferredDefinition":"A category of organic or inorganic substances, elements, and isotopes used in research or for the prevention, diagnosis, and/or treatment of disease states. Includes biologically active substances that are either synthetically manufactured or endogenous substances extracted and processed to be reintroduced into an organism. Chemicals and drugs also include hazardous substances, and naturally occurring or synthetically produced substances required to maintain life.","longName":"C1908","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07431EBC-FB04-25D9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2229718","version":"1","preferredName":"Name","preferredDefinition":"The words or language units by which a thing is known.","longName":"C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F6EF4E2B-76AE-72C1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-05-16","modifiedBy":"ONEDATA","dateModified":"2005-05-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1CF65F2B-8D42-3AE8-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-08","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-09-08","modifiedBy":"LISU","dateModified":"2020-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2194255","version":"1","longName":"Type of Condition","context":"DCP","ClassificationSchemeItems":[{"publicId":"2812152","version":"1","longName":"Barretts Esophagus - ASA-Esomeprazole","context":"DCP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"This information completed on","type":"Preferred Question Text","description":"This information completed on","url":null,"context":"DCP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"1CF65F2B-8D57-3AE8-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-08","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-09-08","modifiedBy":"REEVESD","dateModified":"2011-03-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}